TScan Therapeutics

IPO

Engineering Immunity

Public · Waltham, United States · Founded 2018 · $190.0M raised

Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$190.0M
Last Round
$30.0M Corporate RoundDec 2024
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 6 funding rounds and 4 investors for this company. The full record is or through the API.

About

TScan Therapeutics is a fully integrated clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for patients with cancer and autoimmune disorders. Founded in 2018, its lead candidate TSC-101 targets AML and MDS patients undergoing allogeneic transplant, with a Phase 3 trial expected in 2026.

Summary

TScan Therapeutics is a Biotech company based in Waltham, United States, founded in 2018. It has raised $190.0M in total across 4 rounds, most recently a $30.0M Corporate Round in Dec 2024. Investors include Lynx1 Capital Management, BlackRock and RA Capital Management.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Corporate RoundCorporate RoundDec 2024
$30.0M

Sign up to see all 6 events

Funding: Series A through Corporate Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$2.3BJun 2018
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

TScan Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/tscan-therapeutics"><img src="https://indexed.vc/api/badge/company/tscan-therapeutics" alt="TScan Therapeutics on Indexed.vc" width="260" height="76" /></a>